Biomarkers /
SMO
Overview
SMO (smoothened, frizzled class receptor) is a gene that encodes smoothened homolog, a transmembrane receptor protein that delivers signals from Hedgehog ligands to cells. Mutations in SMO that lead to constitutive activation of SMO are known to play a role in carcinogenesis of basal cell carcinoma, glioblastoma, medulloblastoma, and rhabdomyosarcoma (PMID: 21679342).
SMO is altered in 1.64% of all cancers with lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and cutaneous melanoma having the greatest prevalence of alterations [3].
The most common alterations in SMO are SMO Mutation (1.47%), SMO Amplification (0.16%), SMO P694fs (0.11%), SMO L23dup (0.06%), and SMO Loss (0.07%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of SMO in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.